Measuring optical activity in the far-field from a racemic nanomaterial: Diffraction spectroscopy from plasmonic nanogratings

Recent progress in nanofabrication has redrawn the boundaries of the applicability of chiroptical (chiral optical) effects. Chirality, often expressed as a twist in biomolecules, is crucial for pharmaceuticals, where it can result in extremely different chemical properties. Because chiroptical effects are typically very weak in molecules, plasmonic nanomaterials are often proposed as a promising platform to significantly enhance these effects. Unfortunately, the ideal plasmonic nanomaterial has conflicting requirements: Its chirality should enhance that of the chiral molecules and yet it should have no chiroptical response on its own. Here, we propose a unique reconciliation to satisfy the requirements: A racemic plasmonic nanomaterial, consisting of equal amounts of opposite chiral unit cells. We show how diffraction spectroscopy can be used to unveil the presence of chirality in such racemic nanogratings in the far-field. Our experiments are supported by numerical simulations and yield a circular intensity difference of up to 15%. The physical origin is demonstrated by full wave simulations in combination with a Green's function-group-theory-based analysis. Contributions from Circular Dichroism in the Angular Distribution of Photoelectrons (CDAD) and pseudo/extrinsic chirality are ruled out. Our findings enable the far-field measurement and tuning of racemic nanomaterials, which is crucial for hyper-sensitive chiral molecular characterization.V. K. V. acknowledges support from the Royal Society through the University Research Fellowships. We acknowledge Royal Society grants CHG\R1\170067, PEF1\170015 and RGF\EA\180228, as well as STFC grant ST/R005842/1 and EPSRC grant EP/L015544/1. C. W. acknowledges financial support from Cancer Research UK (CRUK) Pioneer Award (C55962/A24669) and Wolfson College, Cambridge, UK. C. W. further acknowledges research support from S. Bohndiek, T. Wilkinson and G. Gordon. X. Z. and G. A. E. V. are grateful for the financial support from the FWO (G090017N) and KU Leuven internal research funds (C24/15/015)

Where does the transport current flow in Bi2Sr2CaCu2O8 crystals?

A new measurement technique for investigation of vortex dynamics is introduced. The distribution of the transport current across a crystal is derived by a sensitive measurement of the self-induced magnetic field of the transport current. We are able to clearly mark where the flow of the transport current is characterized by bulk pinning, surface barrier, or a uniform current distribution. One of the novel results is that in BSCCO crystals most of the vortex liquid phase is affected by surface barriers resulting in a thermally activated apparent resistivity. As a result the standard transport measurements in BSCCO do not probe the dynamics of vortices in the bulk, but rather measure surface barrier properties.Comment: 11 pages, 4 figures, accepted for publication in Natur

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Spin configurations and negative coercivity in epitaxially grown DyFe2/YFe2 superlattices

Molecular beam epitaxial methods have been used to grow single crystal Laves phase DyFe2/YFe2 superlattice samples with a (110) growth direction. In particular, the magnetic properties of the YFe2 dominated multilayer samples [wDyFe2/4wYFe2]XN with w=20, 30, 40, 45, 50, and 55 Å are presented and discussed. In principle, the multilayer films should possess similar magnetic properties because they are all nominally Dy0.2Y0.8Fe2. However, it is shown that their magnetic properties depend strongly on the thickness of the DyFe2 layers w. Those films with w≥45 Å possess negative coercivities, while those with w≤40 Å are positive. It is argued that this behavior can be understood in terms of a strong increase of the intrinsic coercivity of the DyFe2/YFe2 superlattice, taken as a whole, as w is reduced. For w≤40 Å almost none of the DyFe2 moments can be flipped over in the available field range (12 T). © 2001 American Institute of Physics

Some universal results for exchange spring magnets and applications to DyFe2/YFe2 superlattices

We present some universal results for exchange springs in multilayer systems with alternating hard and soft layers. In particular, the reduced magnetisation 〈cosθ〉, for both symmetric exchange springs (0→φ→0) and 180° exchange springs (0→π), is given in terms of elliptic functions. The result for the symmetric exchange spring is found to be in good accord with experimental results on MBE grown DyFe2/YFe2 multilayers. © 2002 Elsevier Science B.V. All rights reserved

Current-induced organization of vortex motion in type-II superconductors

When a magnetic field is applied to a type-II superconductor, it penetrates the sample in localized tubes of magnetic flux associated with quantized current vortices; under appropriate conditions, these vortices form an ordered lattice. In a material free of crystal defects, transport currents force this lattice to move and dissipate energy, giving the material a non-zero resistance. The presence of defects, however, can inhibit vortex motion, or even pin vortices to specific locations. Thus, to engineer materials with improved properties it is important to understand the motion of a driven vortex lattice in the presence of different kinds of pinning defects1,2. Recent research has investigated vortex-lattice dynamics in the cases of weak, uniform pinning and strong but non-uniform pinning. Here we consider a different regime, in which the barriers to vortex motion at sample surfaces3 also play a crucial role. Our experiments on clean, detwinned YBa2Cu3O7–delta crystals at temperatures around 80–90K reveal an interplay between surface pinning and weak bulk pinning that leads to the formation of a defect superstructure in the vortex lattice. This current-induced organization is similar to phenomena observed in the dynamics of sliding charge-density waves, and represents a fundamentally new kind of vortex dynamics